Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P07949
UPID:
RET_HUMAN
Alternative names:
Cadherin family member 12; Proto-oncogene c-Ret
Alternative UPACC:
P07949; A8K6Z2; Q15250; Q9BTB0; Q9H4A2
Background:
The Proto-oncogene tyrosine-protein kinase receptor Ret, also known as Cadherin family member 12, plays a pivotal role in cell proliferation, neuronal navigation, cell migration, and differentiation. It is crucial for organogenesis, including the development of the enteric nervous system and kidneys, and modulates cell adhesion and migration in an integrin-dependent manner.
Therapeutic significance:
Ret's involvement in diseases such as Colorectal cancer, Hirschsprung disease 1, Medullary thyroid carcinoma, Multiple neoplasia 2B, Pheochromocytoma, and Multiple neoplasia 2A highlights its potential as a therapeutic target. Understanding Ret's role could lead to novel treatments for these conditions.